BioSpace News Archive

- Patients treated with mirikizumab met the primary endpoint of clinical remission and all key secondary endpoints compared to placebo - LUCENT-1 is the first and only Phase 3 study of an anti-IL-23p19 monoclonal antibody to demonstrate reduced bowel urgency in moderate to severe ulcerative colitis - Safety results in this study were consistent with that of the previous mirikizumab study in ulcerative colitis and studies with the anti-IL-23p19 antibody class

Data show more than 50 percent of adults with active PsA achieved complete skin clearance (PASI 100) and more than 70 percent achieved at least 20 percent improvement in joint symptoms (ACR 20)

Global Blood Therapeutics, Inc. announced it has entered into an agreement with Sanofi S.A. to exclusively in-license worldwide rights to two early-stage research programs in sickle cell disease : one that pursues a novel anti-sickling mechanism and another that leverages a new approach to reduce inflammation and oxidative stress.

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases, announced it has completed enrollment for its Phase 2b OPTION 2 clinical trial to investigate MS1819 in cystic fibrosis patients with exocrine pancreatic insufficiency.

Independent, retrospective review of 2016-2019 surgeon data by University of Washington researchers demonstrates that Conformis iTotal® knee replacement implants enable expedited surgical time and reduce length of hospital stay.

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, announced it will host a Virtual Rare Disease Forum on Tuesday, March 23rd, 2021 from 1:00pm to 3:00pm ET.

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company” or “Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced the appointment of Beth P. Hecht to the Company’s Board of Directors replacing Patrick Heron

Iridia™, Inc., a pioneer in fully integrated DNA-based memory chips, today announced that it has closed its Series B financing at a total of $24 million.

Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced therapeutic medicine for mainstream use, announced that it has appointed Michel Rudolphie, former CEO and President of Make-A-Wish International and former Novartis Norway CEO, as President of the Company’s European Operation

InMode Ltd., a leading global provider of innovative medical technologies, has filed a complaint with the United States International Trade Commission alleging ILOODA’s SecretRF fractional radio frequency microneedling system, distributed in the United States by Cutera, Inc., infringes U.S. Patent No. 10,799,285.